Tue, April 5, 2022

Balaji Prasad Upgraded (TEVA) to Buy and Increased Target to $13 on, Apr 5th, 2022

Balaji Prasad of Barclays, Upgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Buy and Increased Target from $11 to $13 on, Apr 5th, 2022.

Balaji has made no other calls on TEVA in the last 4 months.



There is 1 other peer that has a rating on TEVA. Out of the 1 peers that are also analyzing TEVA, all agrees with Balaji's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jasper Hellweg of "Argus Research" Downgraded from Strong Buy to Hold on, Thursday, January 27th, 2022